Compare KYN & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KYN | ELVN |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2004 | 2020 |
| Metric | KYN | ELVN |
|---|---|---|
| Price | $14.06 | $58.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $43.40 |
| AVG Volume (30 Days) | 370.4K | ★ 959.1K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 8.99% | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.31 | $14.79 |
| 52 Week High | $15.17 | $61.29 |
| Indicator | KYN | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 44.02 | 65.21 |
| Support Level | $13.62 | $25.63 |
| Resistance Level | $14.35 | N/A |
| Average True Range (ATR) | 0.26 | 3.06 |
| MACD | -0.07 | 0.38 |
| Stochastic Oscillator | 8.95 | 69.59 |
Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.